Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Value of Prophylactic Plasma Treatment and Incidence of Acute Episodes in Patients Enrolled in the International Hereditary Thrombotic Thrombocytopenic Purpura Registry

Blood (2023) 142 (Supplement 1): 691.

https://doi.org/10.1182/blood-2023-184580

Published: 2023

Journal Articles

Efficacy and Safety of Concizumab Prophylaxis in Patients with Hemophilia A or B without Inhibitors: 56-Week Cut-Off Results of the Phase 3 explorer8 Study

Jan Astermark, Shashikant Apte, Chuhl Joo Lyu, Amalie Rhode Høgh Nielsen, Sonata Saulyte Trakymiene, Jay Jay Thaung Zaw, Huyen Tran, Jerzy Windyga, Hermann Eichler

Blood (2023) 142 (Supplement 1): 2609.

https://doi.org/10.1182/blood-2023-173118

Published: 2023

Journal Articles

Insight into the Natural History of Hereditary Thrombotic Thrombocytopenic Purpura: Short- and Long-Term Outcomes in a Longitudinally Followed Large Patient Cohort of the International Hereditary TTP Registry

Blood (2023) 142 (Supplement 1): 4003.

https://doi.org/10.1182/blood-2023-185053

Published: 2023

Journal Articles

Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1

Blood (2022) 140 (Supplement 1): 5597–5599.

https://doi.org/10.1182/blood-2022-156110

Published: 2022

Journal Articles

Personalization of Clotting Factor VIII Replacement Therapy Based on Population Pharmacokinetics in Adult Patients with Severe Hemophilia a Who Frequently Switch Factor VIII Concentrates

Jerzy Windyga, Edyta Odnoczko, Ewa Stefanska-Windyga, Beata Baran, Anna Sikorska, Magdalena Gorska-Kosicka, Janusz Zawilski, Magdalena Letowska

Blood (2022) 140 (Supplement 1): 8451–8452.

https://doi.org/10.1182/blood-2022-164998

Published: 2022

Journal Articles

Emicizumab in Management of Hemophilia_A Patients with High Titer FVIII Inhibitor - Real-World Evidence from Poland

Jerzy Windyga, Joanna Zdziarska, Ewa Stefanska-Windyga, Ewa Chmielewska, Krzysztof Chojnowski, Michal Jamrozik, Aleksandra Kostyra, Justyna Kozinska, Halyna Krainiak, Jolanta Oleksiuk, Joanna Rupa-Matysek, Ewa Zarzycka, Anna Buczma

Blood (2022) 140 (Supplement 1): 5621–5622.

https://doi.org/10.1182/blood-2022-163567

Published: 2022

Journal Articles

Active Lifestyle in Patients with Hemophilia A or B with Inhibitors on Once-Daily Subcutaneous Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study

Laura Villarreal Martinez, Katarina Cepo, Jannie Laursen, Jan Odgaard-Jensen, Chur-Woo You, Jerzy Windyga

Blood (2022) 140 (Supplement 1): 5634–5636.

https://doi.org/10.1182/blood-2022-167076

Published: 2022

Journal Articles

A Multiple Ascending Dose Study of Mim8 in Patients with Severe Hemophilia a with or without Factor VIII Inhibitors

Steven R. Lentz, Pratima Chowdary, Francisco Jose Lopez Jaime, Johnny Mahlangu, Irina Matytsina, Anne Louise Nielsen, Jerzy Windyga

Blood (2022) 140 (Supplement 1): 2735–2736.

https://doi.org/10.1182/blood-2022-160043

Published: 2022

Journal Articles

Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age

Blood (2021) 138 (Supplement 1): 3195.

https://doi.org/10.1182/blood-2021-147434

Published: 2021

Journal Articles

Prophylactic Treatment with Rurioctocog Alfa Pegol Results in a Dose-Dependent Normalization of Biomarkers of Joint Health in Severe Hemophilia a: An Exploratory Analysis from the Propel Study

Tina Manon-Jensen, Srilatha Tangada, Cecilie Bager, Pratima Chowdary, Robert Klamroth, Annette von Drygalski, Jerzy Windyga, Miguel A. Escobar, Peder Frederiksen, Werner Engl, Bruce Ewenstein, Morten Karsdal

Blood (2021) 138 (Supplement 1): 2102.

https://doi.org/10.1182/blood-2021-150139

Published: 2021

Journal Articles

Recombinant Porcine Factor VIII in Patients with Congenital Hemophilia a with Inhibitors Undergoing Surgery: Phase 3, Multicenter, Single Arm, Open-Label Study

Christian Pfrepper, Paolo Radossi, Jerzy Windyga, Kaan Kavakli, Roger E.G. Schutgens, Nazan Sarper, Jovanna Baptista, Kayode Badejo, Bruce Ewenstein, Nisha Jain

Blood (2021) 138 (Supplement 1): 2109.

https://doi.org/10.1182/blood-2021-146179

Published: 2021

Journal Articles

Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A with FVIII Inhibitors: Final Analysis

Giancarlo Castaman, Jerzy Windyga, Hazza Alzahrani, Susan Robson, Fabian Sanabria, Monet Howard, Víctor Jiménez-Yuste

Blood (2021) 138 (Supplement 1): 344.

https://doi.org/10.1182/blood-2021-145890

Published: 2021

Journal Articles

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

Claude Négrier, Johnny Mahlangu, Michaela Lehle, Pratima Chowdary, Olivier Catalani, Víctor Jiménez-Yuste, Benjamin M. Beckermann, Christophe Schmitt, Cedric Hermans, Giuliana Ventriglia, Jerzy Windyga, Anna Kiialainen, Roseline d'Oiron, Paul Moorehead, Vanda Teodoro, Amy D. Shapiro, Johannes Oldenburg

Blood (2021) 138 (Supplement 1): 343.

https://doi.org/10.1182/blood-2021-146009

Published: 2021

Journal Articles

Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura

Erika Tarasco, Lukas Bütikofer, Kenneth D. Friedman, James N. George, Ingrid Hrachovinova, Paul N. Knöbl, Masanori Matsumoto, Anne Sophie von Krogh, Isabella Aebi-Huber, Zuzana Cermakova, Magdalena Górska-Kosicka, Katarzyna A. Jalowiec, Carlo R. Largiadèr, Zoltán Prohászka, György Sinkovits, Jerzy Windyga, Bernhard Lämmle, Johanna A. Kremer Hovinga

Blood (2021) 137 (25): 3563–3575.

https://doi.org/10.1182/blood.2020009801

Published: 2021

Includes: Supplemental data

Journal Articles

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Robert Klamroth, Jerzy Windyga, Vlad Radulescu, Peter W. Collins, Oleksandra Stasyshyn, Hishamshah Mohd Ibrahim, Werner Engl, Srilatha D. Tangada, William Savage, Bruce Ewenstein

Blood (2021) 137 (13): 1818–1827.

https://doi.org/10.1182/blood.2020005673

Published: 2021

Includes: Supplemental data

Journal Articles

Real-World Clinical Management of Patients with Congenital Hemophilia and Inhibitors: Interim Analysis of the FEIBA Global Outcome Study (FEIBA GO)

Cedric Hermans, MDMRCP,PhD, Claude Négrier, Pål A Holme, Carmen Escuriola, Ana R Cid, Nataliya Kemenyash, MSc, Jaco Botha, Viridiana Cano-Garcia, Jerzy Windyga

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139298

Published: 2020

Journal Articles

Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

Jerzy Windyga, Pal A Holme, C. Hermans, Ana R Cid, Nirjhar Chatterjee, Hongyu Jiang, Viridiana Cano-Garcia, Carmen Escuriola

Blood (2019) 134 (Supplement_1): 2418.

https://doi.org/10.1182/blood-2019-124324

Published: 2019

Journal Articles

Immune Tolerance Induction (ITI) in Paediatric and Adult Patients with Haemophilia a (HA) and High-Titre (HT) Factor VIII (FVIII) Inhibitor - Real Life Data

Magdalena Katarzyna Letowska, Krystyna Zawilska, MD PhD, Anna Klukowska, MD PhD, Krzysztof Chojnowski, MD PhD, Joanna Zdziarska, MD PhD, Ewa Stefanska-Windyga, MD PhD, Jerzy Windyga

Blood (2019) 134 (Supplement_1): 4942.

https://doi.org/10.1182/blood-2019-122422

Published: 2019

Journal Articles

Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies

Victor Jimenez-Yuste, Midori Shima, MD PhD, Ido Paz-Priel, Aric Parnes, Michaela Lehle, Adam Giermasz, Avrita Campinha-Bacote, Markus Niggli, Jerzy Windyga, Sammy Chebon, Peter Trask, Johnny Mahlangu, Steven Pipe, Johannes Oldenburg

Blood (2018) 132 (Supplement 1): 1187.

https://doi.org/10.1182/blood-2018-99-118132

Published: 2018

Journal Articles

Evaluation of the Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma (BAX326) in Previously Treated and Naïve Patients with Severe or Moderately Severe Hemophilia B: A Continuation Study

Jerzy Windyga, Oleksandra Stasyshyn, MD PhD, Werner Engl, PhD CStat, Srilatha D. Tangada, PhD

Blood (2018) 132 (Supplement 1): 1197.

https://doi.org/10.1182/blood-2018-99-111295

Published: 2018

NARROW

Value of Prophylactic Plasma Treatment and Incidence of Acute Episodes in Patients Enrolled in the International Hereditary Thrombotic Thrombocytopenic Purpura Registry

Efficacy and Safety of Concizumab Prophylaxis in Patients with Hemophilia A or B without Inhibitors: 56-Week Cut-Off Results of the Phase 3 explorer8 Study

Insight into the Natural History of Hereditary Thrombotic Thrombocytopenic Purpura: Short- and Long-Term Outcomes in a Longitudinally Followed Large Patient Cohort of the International Hereditary TTP Registry

Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1

Personalization of Clotting Factor VIII Replacement Therapy Based on Population Pharmacokinetics in Adult Patients with Severe Hemophilia a Who Frequently Switch Factor VIII Concentrates

Emicizumab in Management of Hemophilia_A Patients with High Titer FVIII Inhibitor - Real-World Evidence from Poland

Active Lifestyle in Patients with Hemophilia A or B with Inhibitors on Once-Daily Subcutaneous Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study

A Multiple Ascending Dose Study of Mim8 in Patients with Severe Hemophilia a with or without Factor VIII Inhibitors

Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age

Prophylactic Treatment with Rurioctocog Alfa Pegol Results in a Dose-Dependent Normalization of Biomarkers of Joint Health in Severe Hemophilia a: An Exploratory Analysis from the Propel Study

Recombinant Porcine Factor VIII in Patients with Congenital Hemophilia a with Inhibitors Undergoing Surgery: Phase 3, Multicenter, Single Arm, Open-Label Study

Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A with FVIII Inhibitors: Final Analysis

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Real-World Clinical Management of Patients with Congenital Hemophilia and Inhibitors: Interim Analysis of the FEIBA Global Outcome Study (FEIBA GO)

Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

Immune Tolerance Induction (ITI) in Paediatric and Adult Patients with Haemophilia a (HA) and High-Titre (HT) Factor VIII (FVIII) Inhibitor - Real Life Data

Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies

Evaluation of the Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma (BAX326) in Previously Treated and Naïve Patients with Severe or Moderately Severe Hemophilia B: A Continuation Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only